Serum matrix metallopeptidase-9 levels in infantile epileptic spasms syndrome of unknown etiology

• Published in: Epilepsy research Vol. 207; p. 107454
• Main Authors: Matsuura, Ryuki, Hamano, Shin-ichiro, Koichihara, Reiko, Takeda, Rikako, Takeuchi, Hirokazu, Hirata, Yuko, Kikuchi, Kenjiro, Oka, Akira
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2024
• Subjects: Anticonvulsants - therapeutic use; biomarker; Biomarkers - blood; blood–brain barrier; Child, Preschool; diagnosis; epilepsy; Female; Humans; Infant; Male; matrix metallopeptidase-9, predictor; Matrix Metalloproteinase 9 - blood; Prospective Studies; Spasms, Infantile - blood; Spasms, Infantile - diagnosis; Tissue Inhibitor of Metalloproteinase-1 - blood; epilepsy; BBB; TIMP-1; MRI; CI; EEG; ACTH; diagnosis; biomarker; AUC; MMP; blood–brain barrier; CSF; CRH; IESS; matrix metallopeptidase-9, predictor
• ISSN: 0920-1211; 1872-6844; 1872-6844
• DOI: 10.1016/j.eplepsyres.2024.107454

Epileptic spasms are the primary symptom of infantile epileptic spasms syndrome (IESS); however, their direct impact on blood–brain barrier (BBB) function is unknown. Matrix metallopeptidase-9 (MMP-9), degrades type IV collagen, a key component of the blood-brain barrier, while tissue inhibitor of metalloproteinase-1 (TIMP-1) suppresses its activity, protecting BBB integrity. This study aimed to assess serum MMP-9 and TIMP-1 levels in patients with IESS of unknown etiology. We prospectively assessed serum MMP-9 and TIMP-1 levels prior to administering vigabatrin or adrenocorticotropic hormone therapy in patients with IESS of unknown etiology at Saitama Children’s Medical Center between February 2012 and December 2023. We compared these biomarkers between patients with epileptic spasms and age-matched controls and performed a curve regression analysis between the biomarkers and the frequency of epileptic spasms. Additionally, we assessed whether MMP-9 and TIMP-1 levels were diagnostic predictors of IESS. This study included 22 patients with IESS (11 males) and 12 controls. Serum MMP-9 and MMP-9/TIMP-1 ratios were higher in patients with IESS than in controls (p < 0.001 and p = 0.002, respectively). A high frequency of epileptic spasms also led to higher serum MMP-9 levels (y = 0.0871x2 + 0.195x + 195.15, R² = 0.77, p < 0.001). Using MMP >188 ng/mL as the cutoff level, the sensitivity for diagnosing IESS was 95.5 %, the specificity was 75.0 %, the positive likelihood ratio was 3.82 (95 % confidence interval (CI) 1.43–10.22), and the relative risk was 8.75 (95 % CI 1.36–56.5). Patients with IESS had elevated serum MMP-9 levels, suggesting an association between epileptic spasms and blood–brain barrier dysfunction. MMP-9 level measurement may be useful for diagnosing suspected patients. •MMP-9 and TIMP-1 levels analyzed in infantile epileptic spasms syndrome (IESS).•Serum MMP-9 levels were higher in patients with IESS than in healthy controls.•IESS spasms related to BBB dysfunctions are associated with dysregulated MMP-9.•MMP-9 level could be a diagnostic predictors for IESS.